Regulatory News:
NANOBIOTIX (Euronext: NANO ISIN: FR0011341205), a French company pioneer in nanomedicine developing NanoXray, a revolutionary therapeutic approach to local cancer treatment, today announces its revenues for the 4th quarter and full year 2012.
Quaterly revenues and for 2012
* in 2011 the Company recorded no revenue
In the 4th quarter of 2012, the Companys revenues came to 46,409, which corresponds to the pro rata share, over such quarter, of the 810,640 upfront paymentreceived within the framework of a license contract with PharmaEngine for the Asia-Pacific region. The revenue is comparable to the one recorded over the 3rd quarter 2012, totaling 74,153 over the year. This amount is in line with the Companys strategic plan; its business model being based on the commercialization of NBTXR3, which implies to first focus on the products development and clinical approval by the relevant authorities.
Public funding for research expenditures, which comprises research tax credit, is not included in the revenues but is part of the Companys operating revenues, released with half and full year results.
As a reminder, since the Companys IPO on the regulated market of NYSE Euronext in Paris, several major events have marked the end of the year:
Next Financial press release: annual results, April 29, 2013
About NBTXR3
NBTXR3, the lead compound of NANOBIOTIXs NanoXray product pipeline, is a nanoparticle formulation of hafnium oxide crystals for the local treatment of tumors to enhance the efficacy of radiotherapy. NBTXR3 has been classified in the EU as class III medical device and is currently being tested in a European Phase I trial to establish feasibility and safety of NBTXR3 in patients with advanced soft tissue sarcoma. Further clinical trials are in preparation in Europe, in Asia-Pacific (through the PharmaEngine partnership) and in the United States, where NBTXR3 is classified as a drug by the FDA.
See the original post:
NANOBIOTIX: 2012 Revenues